Studies in breast cancer have shown that patients with high CD9 expression have significantly higher overall and relapse-free survival, and those with metastatic disease with high CD9 levels respond better to therapy [3,4,5,6]. This evidence concerns the gene CD9 and metastatic neoplasm.